{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:33:51Z","timestamp":1762900431627,"version":"3.45.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jhepr.2019.11.001","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T19:37:48Z","timestamp":1574105868000},"page":"480-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2489-0768","authenticated-orcid":false,"given":"Pierre","family":"Nahon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Ganne-Carri\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2019.11.001_bib1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","article-title":"What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?","volume":"156","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib3","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jhep.2016.08.001","article-title":"Management of the patient with SVR","volume":"65","author":"Terrault","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/hep.27743","article-title":"Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)","volume":"62","author":"Trinchet","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/hep.27598","article-title":"The clinical course of cirrhosis: the importance of multistate models and competing risks analysis","volume":"62","author":"Jepsen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically\u00a0advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/annonc\/mdy510","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Vogel","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib11","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","author":"Farhang Zangneh","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Annals of internal medicine"},{"key":"10.1016\/j.jhepr.2019.11.001_bib13","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhepr.2019.11.001_bib14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1053\/j.gastro.2016.12.021","article-title":"Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis","volume":"152","author":"Ravi","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/gutjnl-2015-310033","article-title":"Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN\u03b1","volume":"66","author":"Serti","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2019.11.001_bib19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1053\/j.gastro.2017.10.035","article-title":"Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals","volume":"154","author":"Debes","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib20","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/hep.29911","article-title":"Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals","volume":"68","author":"Faillaci","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jhep.2019.01.005","article-title":"Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules","volume":"70","author":"Marino","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib22","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2017.10.033","article-title":"The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen","volume":"68","author":"Innes","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib24","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","author":"Ioannou","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib25","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib26","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2019.11.001_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib28","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib29","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1002\/hep.29707","article-title":"The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study","volume":"67","author":"Li","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","article-title":"Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication","volume":"66","author":"van der Meer","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib31","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1007\/s00535-013-0921-z","article-title":"Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes","volume":"49","author":"Yamashita","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"El-Serag","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","article-title":"Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients","volume":"49","author":"George","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/liv.12576","article-title":"Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis","volume":"35","author":"Akhtar","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.11.001_bib35","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hepr.12331","article-title":"Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response","volume":"45","author":"Tachi","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2019.11.001_bib37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2019.11.001_bib38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"Bachofner","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.11.001_bib39","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/liv.13707","article-title":"Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression","volume":"38","author":"D'Ambrosio","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.11.001_bib40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/apt.13722","article-title":"The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study","volume":"44","author":"Sultanik","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2019.11.001_bib41","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/liv.13179","article-title":"Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy","volume":"36","author":"Wang","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.11.001_bib42","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","author":"Kanwal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib43","doi-asserted-by":"crossref","first-page":"h6080","DOI":"10.1136\/bmj.h6080","article-title":"Why cancer screening has never been shown to \u201csave lives\u201d\u2013and what we can do about it","volume":"352","author":"Prasad","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jhepr.2019.11.001_bib44","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib45","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaoncol.2016.3147","article-title":"MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma","volume":"3","author":"Kim","year":"2017","journal-title":"JAMA oncology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.cgh.2015.12.042","article-title":"Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients","volume":"14","author":"Berhane","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2012.02.035","article-title":"Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis","volume":"57","author":"Nahon","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-0037-1607452","article-title":"HCC risk scores: useful or not?","volume":"37","author":"Sherman","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2019.11.001_bib49","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2018.07.024","article-title":"Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C","volume":"69","author":"Ioannou","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib50","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1038\/ctg.2017.26","article-title":"Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis","volume":"8","author":"Goossens","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib51","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib52","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib53","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/hep.23528","article-title":"Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","article-title":"Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension","volume":"151","author":"Di Marco","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib55","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib56","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2018.11.053","article-title":"Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy","volume":"156","author":"Thabut","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib57","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/gutjnl-2015-310275","article-title":"Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)","volume":"66","author":"Nahon","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2019.11.001_bib58","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2019.11.001_bib59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2019.11.001_bib60","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib61","doi-asserted-by":"crossref","first-page":"7305","DOI":"10.1038\/sj.onc.1206936","article-title":"Retinoids in cancer therapy and chemoprevention: promise meets resistance","volume":"22","author":"Freemantle","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jhepr.2019.11.001_bib62","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib63","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","article-title":"Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort)","volume":"13","author":"Gentile","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2019.11.001_bib64","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/apt.14404","article-title":"Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD >\/= 15)","volume":"47","author":"McCaughan","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2019.11.001_bib65","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A\u00a0sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C","volume":"9","author":"Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib66","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.29408","article-title":"Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease","volume":"69","author":"Backus","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib67","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/hep.22703","article-title":"Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C","volume":"49","author":"Arase","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib68","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cgh.2010.01.022","article-title":"Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial","volume":"8","author":"Delgado-Borrego","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib69","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc17-0485","article-title":"Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus","volume":"40","author":"Hum","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhepr.2019.11.001_bib70","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/hrt.2003.018937","article-title":"Evidence for association between hepatitis C virus seropositivity and coronary artery disease","volume":"90","author":"Vassalle","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.jhepr.2019.11.001_bib71","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(02)07339-7","article-title":"Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening","volume":"359","author":"Ishizaka","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2019.11.001_bib72","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2019.11.001_bib73","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib74","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/gut.2009.202317","article-title":"Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors","volume":"59","author":"Mostafa","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2019.11.001_bib75","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ahj.2017.10.024","article-title":"Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients","volume":"198","author":"Cacoub","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jhepr.2019.11.001_bib76","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrgastro.2017.172","article-title":"Extrahepatic cancers and chronic HCV infection","volume":"15","author":"Pol","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib77","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jhepr.2019.11.001_bib78","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/ijc.30372","article-title":"Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma","volume":"139","author":"Hosry","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhepr.2019.11.001_bib79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jhep.2016.08.004","article-title":"Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population","volume":"66","author":"Innes","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib80","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.30034","article-title":"Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication","volume":"68","author":"Allaire","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib81","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2016.10.042","article-title":"Mailed outreach program increases ultrasound screening of patients with cirrhosis for hepatocellular carcinoma","volume":"152","author":"Singal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib82","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.04.027","article-title":"Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study","volume":"155","author":"Costentin","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib83","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","author":"Chung","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhepr.2019.11.001_bib84","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.26442","article-title":"alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C","volume":"58","author":"Asahina","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib85","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cgh.2019.04.062","article-title":"Performance of Baveno VI and Expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"17","author":"Stafylidou","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cgh.2018.03.012","article-title":"Screening and surveillance of varices in patients with cirrhosis","volume":"17","author":"Jakab","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib87","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1046\/j.1365-2036.2003.01546.x","article-title":"Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study","volume":"17","author":"Hezode","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2019.11.001_bib88","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/MCG.0b013e3181e12511","article-title":"Mild alcohol consumption is not associated with increased fibrosis in patients with chronic hepatitis C","volume":"45","author":"Cheung","year":"2011","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib89","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2016.04.031","article-title":"Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: a prospective study","volume":"65","author":"Vandenbulcke","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2019.11.001_bib90","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep.28702","article-title":"Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)","volume":"64","author":"Ganne-Carrie","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.11.001_bib91","doi-asserted-by":"crossref","first-page":"872152","DOI":"10.1155\/2015\/872152","article-title":"Liver cirrhosis: evaluation, nutritional status, and prognosis","volume":"2015","author":"Nishikawa","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jhepr.2019.11.001_bib92","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/bjsports-2016-096197","article-title":"Effect of exercise training on liver function in adults who are overweight or exhibit fatty liver disease: a systematic review and meta-analysis","volume":"52","author":"Smart","year":"2018","journal-title":"Br J Sports Med"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555919301326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555919301326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:23:36Z","timestamp":1762899816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555919301326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S2589555919301326"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2019.11.001","relation":{},"ISSN":["2589-5559"],"issn-type":[{"type":"print","value":"2589-5559"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2019.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}]}}